Long-term effects of neonatal treatment with fluoxetine on cognitive performance in Ts65Dn mice
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
Individuals with Down syndrome (DS), a genetic condition caused by triplication of chromosome 21, are characterized by intellectual disability and are prone to develop Alzheimer's disease (AD), due to triplication of the amyloid precursor protein (APP) gene. Recent evidence in the Ts65Dn mouse model of DS shows that enhancement of serotonergic transmission with fluoxetine during the perinatal period rescues neurogenesis, dendritic pathology and behavior, indicating that cognitive impairment can be pharmacologically restored. A crucial question is whether the short-term effects of early treatments with fluoxetine disappear at adult life stages. In the current study we found that hippocampal neurogenesis, dendritic pathology and hippocampus/amygdala-dependent memory remained in their restored state when Ts65Dn mice, which had been neonatally treated with fluoxetine, reached adulthood. Additionally, we found that the increased levels of the APP-derived βCTF peptide in adult Ts65Dn mice were normalized following neonatal treatment with fluoxetine. This effect was accompanied by restoration of endosomal abnormalities, a βCTF-dependent feature of DS and AD. While untreated adult Ts65Dn mice had reduced hippocampal levels of the 5-HT1A receptor (5-HT1A-R) and methyl-CpG-binding protein (MeCP2), a protein that promotes 5-HT1A-R transcription, in neonatally-treated mice both 5-HT1A-R and MeCP2 were normalized. In view of the crucial role of serotonin in brain development, these findings suggest that the enduring outcome of neonatal treatment with fluoxetine may be due to MeCP2-dependent restoration of the 5-HT1A-R. Taken together, results provide new hope for the therapy of DS, showing that early treatment with fluoxetine enduringly restores cognitive impairment and prevents early signs of AD-like pathology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MeCP2, a Key Contributor to Neurological Disease, Activates and Represses Transcription
Chahrour, M., Jung, S. Y., Shaw, C., Zhou, X., Wong, S. T. C., Qin, J., & Zoghbi, H. Y. (2008) · Science · doi:10.1126/science.1153252 · Cited by 1,823
Distinct morphological stages of dentate granule neuron maturation in the adult mouse hippocampus
Zhao, C., Teng, E. M., Summers, R. G., Ming, G.-L., & Gage, F. H. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.3648-05.2006 · Cited by 1,257
A mouse model for Down syndrome exhibits learning and behaviour deficits
Reeves, R. H., Irving, N. G., Moran, T. H., Wohn, A., Kitt, C., Sisodia, S. S., Schmidt, C., Bronson, R. T., & Davisson, M. T. (1995) · Nature Genetics · doi:10.1038/ng1095-177 · Cited by 913 · cited 1×
“Female Ts65Dn mice carrying a partial trisomy of chromosome 16 (Reeves et al., 1995) were obtained from Jackson Laboratories (Bar Harbour, ME, USA) and the original genetic backgroundwas maintained by mating them with C57BL/6JEi x C3H/HeSnJ (B6EiC3Sn) F1 males.”
MethodAltman, J., & Bayer, S. A. (1990) · Journal of Comparative Neurology · doi:10.1002/cne.903010304 · Cited by 819
Sairanen, M., Lucas, G., Ernfors, P., Castrén, M., & Castrén, E. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.3741-04.2005 · Cited by 763 · cited 2×
“While a previous study in transgenicmicewith reduced BDNF levels or impaired trkB activation showed an increase in apoptotic cell death shortly after chronic treatment with fluoxetine (Sairanen et al., 2005), we found here that in adult Ts65Dn mice that had been neonatally-treated with fluoxetine there was no increase…”
BackgroundFluoxetine targets early progenitor cells in the adult brain
Encinas, J. M., Vaahtokari, A., & Enikolopov, G. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0601992103 · Cited by 637
Serotonin and brain development: role in human developmental diseases
Whitaker-Azmitia, P. M. (2001) · Brain Research Bulletin · doi:10.1016/s0361-9230(01)00615-3 · Cited by 506 · cited 4×
“Since serotonin plays a pivotal role in neurogenesis and dendritic development (Whitaker-Azmitia, 2001) and it requires the 5-HT1A-R for this (Santarelli et al.”
BackgroundInfluentialWhat's Wrong With My Mouse?: Behavioral Phenotyping of Transgenic and Knockout Mice
Crawley, J. N. (2007) · doi:10.1002/0470119055 · Cited by 474
Inhibition of GSK3β-mediated BACE1 expression reduces Alzheimer-associated phenotypes
Ly, P. T. T., Wu, Y., Zou, H., Wang, R., Zhou, W., Kinoshita, A., Zhang, M., Yang, Y., Cai, F., Woodgett, J., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci64516 · Cited by 442 · cited 1×
“A recent study shows that inhibition of GSK3β activity reduces BACE1 expression (Ly et al., 2013).”
BackgroundCirrito, J. R., Disabato, B. M., Restivo, J. L., Verges, D. K., Goebel, W. D., Sathyan, A., Hayreh, D., D'Angelo, G., Benzinger, T., Yoon, H., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1107411108 · Cited by 377 · cited 5×
“Abbreviations: AC, anterior commissure; CC, corpus callosum; SR, septal region; Alzheimer's disease (AD) serotonergic signaling appears to modify APP processing through the 5-HT1A-R, with a reduction in the production of the β-amyloid peptide (Cirrito et al., 2011; Nelson et al., 2007).”
BackgroundInfluentialContestabile, A., Fila, T., Ceccarelli, C., Bonasoni, P., Bonapace, L., Santini, D., Bartesaghi, R., & Ciani, E. (2007) · Hippocampus · doi:10.1002/hipo.20308 · Cited by 281
Self-citationGuidi, S., Bonasoni, P., Ceccarelli, C., Santini, D., Gualtieri, F., Ciani, E., & Bartesaghi, R. (2008) · Brain Pathology · doi:10.1111/j.1750-3639.2007.00113.x · Cited by 276 · cited 2×
“An altered differentiation programcharacterizes trisomic NPCs, with a reduction in the number of cells that acquire a neuronal phenotype and a relative increase in the number of cells that acquire an astrocytic phenotype (Contestabile et al., 2009; Contestabile et al., 2007; Guidi et al., 2008).”
BackgroundSelf-citationCataldo, A. M., Petanceska, S., Peterhoff, C. M., Terio, N. B., Epstein, C. J., Villar, A., Carlson, E. J., Staufenbiel, M., & Nixon, R. A. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-17-06788.2003 · Cited by 241 · cited 5×
“The septal area is a brain region where Ts65Dn mice show endosome alterations starting from 2 months of age (Cataldo et al., 2003).”
BackgroundInfluentialBianchi, P., Ciani, E., Guidi, S., Trazzi, S., Felice, D., Grossi, G., Fernandez, M., Giuliani, A., Calza, L., & Bartesaghi, R. (2010) · Journal of Neuroscience · doi:10.1523/jneurosci.0534-10.2010 · Cited by 188 · cited 11×
“The trisomic brain is characterized by reduced expression of the 5-HT1A receptor starting from early life stages (Bar-Peled et al., 1991; Bianchi et al., 2010; Guidi et al., 2014).”
BackgroundResultInfluentialSelf-citationMolecular characterization of the translocation breakpoints in the down syndrome mouse model Ts65Dn
Reinholdt, L. G., Ding, Y., Gilbert, G. T., Czechanski, A., Solzak, J. P., Roper, R. J., Johnson, M. T., Donahue, L. R., Lutz, C., & Davisson, M. T. (2011) · Mammalian Genome · doi:10.1007/s00335-011-9357-z · Cited by 186
NELSON, R., GUO, Z., HALAGAPPA, V, PEARSON, M., GRAY, A., MATSUOKA, Y., BROWN, M., MARTIN, B., IYUN, T., & MAUDSLEY, S. (2007) · Experimental Neurology · doi:10.1016/j.expneurol.2007.01.037 · Cited by 173 · cited 2×
“Abbreviations: AC, anterior commissure; CC, corpus callosum; SR, septal region; Alzheimer's disease (AD) serotonergic signaling appears to modify APP processing through the 5-HT1A-R, with a reduction in the production of the β-amyloid peptide (Cirrito et al., 2011; Nelson et al., 2007).”
BackgroundGuidi, S., Ciani, E., Bonasoni, P., Santini, D., & Bartesaghi, R. (2011) · Brain Pathology · doi:10.1111/j.1750-3639.2010.00459.x · Cited by 165 · cited 1×
“Considering that one of the most severe defects of trisomy is early neurogenesis impairment (Guidi et al., 2008; Guidi et al., 2011), therapies to improve this defect should be started as soon as possible, otherwise the brainwill have a permanently reduced asset of neurons.”
BackgroundSelf-citationMaternal antidepressant use and adverse outcomes: a cohort study of 228,876 pregnancies
Hayes, R. M., Wu, P., Shelton, R. C., Cooper, W. O., Dupont, W. D., Mitchel, E., & Hartert, T. V. (2012) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2012.04.028 · Cited by 149 · cited 1×
“Antidepressants during pregnancy and during early life stages may have adverse effects, such as growth restriction and a neonatal withdrawal syndrome, though these effects seem to disappear with time (Einarson et al., 2009; Hayes et al., 2012; Olivier et al., 2013; Pedersen et al. et al., 2010).”
BackgroundFetal exposure to antidepressants and normal milestone development at 6 and 19 months of age
Pedersen, L. H., Henriksen, T. B., & Olsen, J. (2010) · Pediatrics · doi:10.1542/peds.2008-3655 · Cited by 144
5-HT1a receptors mediate the neurotrophic effect of serotonin on developing dentate granule cells
Yan, W., Wilson, C. C., & Haring, J. H. (1997) · Developmental Brain Research · doi:10.1016/s0165-3806(96)00175-7 · Cited by 142
Choi, J. H. K., Berger, J. D., Mazzella, M. J., Morales‐Corraliza, J., Cataldo, A. M., Nixon, R. A., Ginsberg, S. D., Levy, E., & Mathews, P. M. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06277.x · Cited by 83 · cited 1×
“Surprisingly, other studies failed to find significant differences in APP levels in mice younger than 12 months (Choi et al., 2009; Hunter et al., 2003a, 2003b; Seo and Isacson, 2005).”
Pechnick, R. N., Zonis, S., Wawrowsky, K., Cosgayon, R., Farrokhi, C., Lacayo, L., & Chesnokova, V. (2011) · PLoS ONE · doi:10.1371/journal.pone.0027290 · Cited by 78 · cited 1×
“In euploid mice, inhibition of p21, associated with an increase in hippocampal neurogenesis, was previously described 24 h after chronic treatment with fluoxetine (Pechnick et al., 2011).”
BackgroundAltafaj, X., Martín, E. D., Ortiz-Abalia, J., Valderrama, A., Lao-Peregrín, C., Dierssen, M., & Fillat, C. (2013) · Neurobiology of Disease · doi:10.1016/j.nbd.2012.11.017 · Cited by 75
Serotonin and neuronal growth factors—a convergence of signaling pathways
Cowen, D. S. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04420.x · Cited by 72 · cited 3×
“Erk1/ Erk2, which are triggered by activation of various serotonin receptors, including the 5-HT1A-R (Cowen, 2007) are involved in various plasticity”
BackgroundHuang, G.-J., Ben-David, E., Tort Piella, A., Edwards, A., Flint, J., & Shifman, S. (2012) · PLoS ONE · doi:10.1371/journal.pone.0035901 · Cited by 52 · cited 1×
“A more recent study (Huang et al., 2012) highlights a very complex molecular signature of fluoxetine treatment in the brain, with changes in specific networks of genes, suggesting that additional genes/pathways may be involved in the long-term restoration of neurogenesis.”
Background
Cited by
Down syndrome and the complexity of genome dosage imbalance
Antonarakis, S. E. (2017) · Nature Reviews Genetics · doi:10.1038/nrg.2016.154 · Cited by 299
Neurogenesis impairment: An early developmental defect in Down syndrome
Stagni, F., Giacomini, A., Emili, M., Guidi, S., & Bartesaghi, R. (2018) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2017.07.026 · Cited by 120
“Excessive p21 levels have also been found in the hippocampus of young Ts65Dn mice [73].”
Self-citationBlock, A., Ahmed, M. M., Dhanasekaran, A. R., Tong, S., & Gardiner, K. J. (2015) · Biology of Sex Differences · doi:10.1186/s13293-015-0043-9 · Cited by 43
“Fluoxetine is of interest in DS because it has been shown to rescue LM deficits in another mouse model of DS, the Ts65Dn [60–62].”
BackgroundBrain circuit pathology in Down syndrome: from neurons to neural networks
Bartesaghi, R. (2023) · Reviews in the Neurosciences · doi:10.1515/revneuro-2022-0067 · Cited by 25
Self-citationSearching for new pharmacological targets for the treatment of Alzheimer's disease in Down syndrome
Caraci, F., Iulita, M. F., Pentz, R., Flores Aguilar, L., Orciani, C., Barone, C., Romano, C., Drago, F., & Cuello, A. C. (2017) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.10.004 · Cited by 18
Metadata
- Authors
- Stagni, F., Giacomini, A., Guidi, S., Ciani, E., Ragazzi, E., Filonzi, M., De Iasio, R., Rimondini, R., & Bartesaghi, R.
- Venue
- Neurobiology of Disease
- Publisher
- Elsevier BV
- Published
- 2015-02
- Volume
- 74
- Pages
- 204-218
- ISSN
- 0969-9961 (ISSN-L)
- OpenAlex
- W2077917890
- Cited by
- 55
- References
- 25
- FWCI
- 5.82
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.